2023 BDO Healthcare CFO Outlook Survey

February 14, 2023 | 1:00PM EST | USA

2023 BDO

The BDO Healthcare Trends & Topics Webinar Series is produced and delivered by the BDO Center for Healthcare Excellence and Innovation, which brings together an interdisciplinary group of healthcare executives 

Register Now

Spotlight

New data from an ongoing post-marketing study in nearly 45,000 people with non-valvular atrial fibrillation (NVAF) confirm the safety profile of XARELTO® (rivaroxaban) was generally consistent with the findings observed in ROCKET AF, the Phase 3 study that supported the approval of the medicine for prevention of stroke in patients with NVAF.

OTHER LIVE WEBINARS

How AI and sensing can help in building personalized treatments

February 07, 2023 |

As sensors are continuously becoming smaller and cheaper, there’s a great opportunity to generate vast amounts of data for improving our health.
Register Now

The global healthcare supply chain trends

February 09, 2023 | 10:00AM AET

Healthcare is changing faster than ever before. Tomorrow’s fragile biologics are one of today’s most complex logistical challenges. As the future of healthcare continues to take shape, we’re continuing to expand our ability to deliver more for you and our patients.
Register Now

Hot Topics Women's Health

February 04, 2023 |

We are delighted to offer the opportunity to watch the Hot Topics Women's Health course from the comfort of your own home.
Register Now

Preventing, Detecting, and Analyzing Data from Suspected Fraudulent Respondents in Online Surveys, with Examples from Health Preference Studies

February 14, 2023 | 10:00AM EDT

Many surveys, including health preference studies, collect data through web-based instruments. The risk of online data collection fraud is growing, and researchers need to understand the threat and ways to reduce risks to data collection.
Register Now

Spotlight

New data from an ongoing post-marketing study in nearly 45,000 people with non-valvular atrial fibrillation (NVAF) confirm the safety profile of XARELTO® (rivaroxaban) was generally consistent with the findings observed in ROCKET AF, the Phase 3 study that supported the approval of the medicine for prevention of stroke in patients with NVAF.

resources